Meplazumab is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase II for Malaria. According to GlobalData, Phase II drugs for Malaria have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Meplazumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Meplazumab overview
Meplazumab is under development for the treatment of malaria and Coronavirus disease 2019 (COVID-19), post covid-19 and coronavirus disease 2019 (covid-19) pneumonia. Meplazumab, is a humanized immunoglobulin (Ig) G2 monoclonal antibody, consisting of the complementary-determining regions of anti CD147 murine antibody and the human framework region. It is administered through intravenous route. The therapeutic candidate acts by targeting extracellular matrix metalloproteinase inducer (EMMPRIN) or CD147.
Jiangsu Pacific Meinuoke Bio-Pharmarceutical overview
Jiangsu Pacific Meinuoke Bio-Pharmarceutical (Pacific Meinuoke) focuses on the development of novel biopharmaceuticals for addressing the unmet medical needs of patients with cancer and infectious diseases. Pacific Meinuoke is headquartered in Changzhou City, China.
For a complete picture of Meplazumab’s drug-specific PTSR and LoA scores,
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
